Co-agonists of the glucagon and glp-1 receptors

103:

• A composition comprising a peptide having an amino acid sequence as set forth in SEQ ID NO:7, 8, 9, 10, 12, 13, 14, 15, 16, 17, 18, or 19, and a pharmaceutically acceptable carrier.

104:

• The composition of claim 103, wherein the composition further comprises an insulin or insulin analog.

105:

• The composition of claim 104, wherein the insulin analog comprises insulin detemir, insulin glargine, insulin levemir, insulin glulisine, or insulin lispro.

106:

• A method for treating a patient or individual for a metabolic disease comprising administering the patient or individual an effective amount of the composition of claim 103 to treat the metabolic disease in the patient or individual.

107:

• The method of claim 106, wherein the metabolic disease comprises diabetes, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), or obesity.

108:

• The method of claim 107, wherein the diabetes comprises Type I diabetes, Type II diabetes, or gestational diabetes.

109:

• A method for treating a metabolic disease in a patient or individual comprising:
• administering to the patient or individual (i) an effective amount of a composition comprising a peptide having an amino acid sequence as set forth in SEQ ID NO:7, 8, 9, 10, 12, 13, 14, 15, 16, 17, 18, or 19, and a pharmaceutically acceptable carrier, and administering to the patient or individual an effective amount of a composition comprising an insulin or insulin analog and a pharmaceutically acceptable carrier or (ii) an effective amount of a composition comprising a peptide having an amino acid sequence as set forth in SEQ ID NO:7, 8, 9, 10, 12, 13, 14, 15, 16, 17, 18, or 19, an insulin or insulin analog, and a pharmaceutically acceptable carrier,
• wherein the composition treats the metabolic disease.

111:

• The method of claim 109, wherein the insulin analog comprises insulin detemir, insulin glargine, insulin levemir, insulin glulisine, or insulin lispro.

112:

• The method of claim 109, wherein the metabolic disease comprises diabetes, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), or obesity.

113:

• The method of claim 112, wherein the diabetes comprises Type I diabetes, Type II diabetes, or gestational diabetes.